Latest news

• Bavarian Nordic’s COVID-19 booster ‘not suitable’ for emerging variants

  However, ABNCoV2’s ability to neutralise antibodies against the circulating Omicron variant, XBB.1.5, was significantly lower than the original version of Pfizer and BioNTech’s Comirnaty. ... The data showed that 64% of people had detectable

• Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine approved by EC

  Pfizer and BioNTech’s Comirnaty XXB.1.5-adapted COVID-19 vaccine has been approved by the European Commission (EC) for adults, children and infants aged over six months. ... The Comirnaty XBB.1.5-adapted COVID-19 vaccine is currently the third

• Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine recommended by CHMP

  older. The Committee for Medicinal Products for Human Use (CHMP) has specifically recommended marketing authorisation for a single dose of the vaccine, known as Comirnaty Omicron XBB.1.5, in eligible

• MHRA authorises HIPRA Human Health's COVID-19 vaccine for use in UK

  The regulator’s decision was based on data from a study of 765 adults who received primary vaccination with two doses of the Comirnaty COVID-19 vaccine and then a booster ... dose of either Bimervax or Comirnaty.

• BioNTech reveals plans to spend about €1bn more on research and development this year

  In December 2022, the companies announced that approximately two billion doses of Comirnaty were invoiced globally that year, including around 550 million doses of the Original/Omicron BA.4-5-adapted